Find information on thousands of medical conditions and prescription drugs.

Cilostazol

Pletal (pronunced PLAY-tal) is a drug treating symptoms of the medical condition intermittent claudication. It is manufactured by Otsuka Pharmaceutical; the drug's generic name is cilostazol (sil-OS-tah-zol). more...

Home
Diseases
Medicines
A
B
C
Cabergoline
Caduet
Cafergot
Caffeine
Calan
Calciparine
Calcitonin
Calcitriol
Calcium folinate
Campath
Camptosar
Camptosar
Cancidas
Candesartan
Cannabinol
Capecitabine
Capoten
Captohexal
Captopril
Carbachol
Carbadox
Carbamazepine
Carbatrol
Carbenicillin
Carbidopa
Carbimazole
Carboplatin
Cardinorm
Cardiolite
Cardizem
Cardura
Carfentanil
Carisoprodol
Carnitine
Carvedilol
Casodex
Cataflam
Catapres
Cathine
Cathinone
Caverject
Ceclor
Cefacetrile
Cefaclor
Cefaclor
Cefadroxil
Cefazolin
Cefepime
Cefixime
Cefotan
Cefotaxime
Cefotetan
Cefpodoxime
Cefprozil
Ceftazidime
Ceftriaxone
Ceftriaxone
Cefuroxime
Cefuroxime
Cefzil
Celebrex
Celexa
Cellcept
Cephalexin
Cerebyx
Cerivastatin
Cerumenex
Cetirizine
Cetrimide
Chenodeoxycholic acid
Chloralose
Chlorambucil
Chloramphenicol
Chlordiazepoxide
Chlorhexidine
Chloropyramine
Chloroquine
Chloroxylenol
Chlorphenamine
Chlorpromazine
Chlorpropamide
Chlorprothixene
Chlortalidone
Chlortetracycline
Cholac
Cholybar
Choriogonadotropin alfa
Chorionic gonadotropin
Chymotrypsin
Cialis
Ciclopirox
Cicloral
Ciclosporin
Cidofovir
Ciglitazone
Cilastatin
Cilostazol
Cimehexal
Cimetidine
Cinchophen
Cinnarizine
Cipro
Ciprofloxacin
Cisapride
Cisplatin
Citalopram
Citicoline
Cladribine
Clamoxyquine
Clarinex
Clarithromycin
Claritin
Clavulanic acid
Clemastine
Clenbuterol
Climara
Clindamycin
Clioquinol
Clobazam
Clobetasol
Clofazimine
Clomhexal
Clomid
Clomifene
Clomipramine
Clonazepam
Clonidine
Clopidogrel
Clotrimazole
Cloxacillin
Clozapine
Clozaril
Cocarboxylase
Cogentin
Colistin
Colyte
Combivent
Commit
Compazine
Concerta
Copaxone
Cordarone
Coreg
Corgard
Corticotropin
Cortisone
Cotinine
Cotrim
Coumadin
Cozaar
Crestor
Crospovidone
Cuprimine
Cyanocobalamin
Cyclessa
Cyclizine
Cyclobenzaprine
Cyclopentolate
Cyclophosphamide
Cyclopropane
Cylert
Cyproterone
Cystagon
Cysteine
Cytarabine
Cytotec
Cytovene
Isotretinoin
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Although drugs similar to Pletal have increased the risk of death in patients with congestive heart failure, studies of significant size have not addressed people without the disease.

It is not clear how pletal works, but its main effects are dilation of the arteries supplying blood to the legs and decreasing platelet coagulation.

Dosage

Pletal is typically taken in 100mg doses twice a day.

Interactions and side effects

Drugs that interact with Pletal include "itracomazole", "erythromycin", "ketoconazole", "dilitiazem", and "omeprazole". Grapefruit juice interacts with the drug; other citrus juices do not.

Possible side effects of Pletal include headache, diarrhea, abnormal stools, increased heart rate, and palpitations.

Important Note

Cilostazol, clearly effective for a debilitating condition whose current treatment is often inadequate, is a member of a pharmacologic class that is dangerous to people with severe heart failure and unstudied in other people. Cilostazol has been studied in people without heart failure, without evidence of harm, but much more data would be needed to determine that there is no risk at all. Although cilostazol would not be approvable for a trivial condition the Cardio-Renal Advisory Committee and FDA concluded that fully informed patients and physicians should be able to choose to use it to treat intermittent claudication. Patient and physician labeling will describe the basis for concern and the incomplete information available.

Read more at Wikipedia.org


[List your site here Free!]


Is cilostazol more effective than pentoxifylline in the treatment of symptoms of intermittent claudication?
From Journal of Family Practice, 2/1/01 by David Weismantel

Dawson DL, Cutler BS, Hiatt WR, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med 2000; 109:523-30.

* BACKGROUND Pentoxifylline and cilostazol are the only 2 prescription drugs labeled for treatment of intermittent claudication, No studies have compared the relative benefit of these agents. The only other therapy demonstrated to be effective is active exercise intervention, usually in the form of a walking program.

* POPULATION STUDIED The investigators enrolled 698 patients with stable moderate to severe symptoms of intermittent claudication and confirmed peripheral vascular disease. These patients had symptoms present for at least 6 months but without substantial change in the last 3 months. All patients had peripheral vascular disease confirmed by either a resting ankle/brachial index of 0.90 or lower and a 10-mm Hg or higher decrease in ankle pressure measured 1 minute after walking to maxireal walking distance, or a 20-mm Hg or higher decrease in postexercise ankle pressure in the symptomatic extremity. To qualify for study inclusion, the patients needed a baseline pain-free walking distance between 53.5 meters (1 minute on treadmill protocol) and 537.7 meters (10 minutes). The study subjects were 76% men and had an average age of 66 years. Patients were ineligible who had critical lower extremity ischemia, arterial reconstruction, or sympathectomy within the previous 3 months, as were patients with an exercise capacity limited by conditions other than intermittent claudication. The 3 groups were similar in age, sex, race, smoking status, diabetes, hypercholesterolemia, hypertension, and baseline disease severity.

* STUDY DESIGN AND VALIDITY The study was a double-blind multicenter trial with patients randomized using concealed allocation to receive either cilostazol (100 mg orally twice daily), pentoxifylline (400 mg orally 3 times daily), or placebo for a 24-week period. No specific counseling about diet, smoking cessation, or exercise was offered to the patients during the study period. At baseline and every 4 weeks afterward, study participants underwent evaluation including medical history, physical examination, treadmill testing, Doppler limb pressure measurements, and assessment of adverse events.

* OUTCOMES MEASURED The primary study end point was a comparison of the relative effects of cilostazol and pentoxifylline on walking ability, as measured by maximal walking distance on a standardized treadmill test. Secondary end points included pain-free walking distance and resting Doppler limb pressures. Perception of functional ability and quality of life was measured with the Medical Outcomes Scale Short Form-36 (SF-36) and the Walking Impairment Questionnaire. In addition, physicians and patients were asked for their subjective assessment of benefit at the end of treatment.

* RESULTS Using a treadmill protocol and assessed by intention-to treat analysis, cilostazol increased the maximal walking distance by 54% over baseline (average=107 m), compared with a 30% increase with pentoxifylline (P [is less than] .001) and a 34% increase in the placebo group (P [is less than] .001). The improvement with pentoxifylline was similar to that in the placebo group (average=65 m). Walking distances progressively increased in all 3 groups and did not plateau within the 24-week study. Side effects including headache, diarrhea, and abnormal stools occurred more commonly in the cilostazol group, yet the withdrawal rate was similar between the 2 active drug treatment groups (16%-19%). Scores on the SF-36 and the Walking Impairment Questionnaire revealed no significant differences in general health perception or patient-reported walking distance. In subjective assessment by patients, 51% of the cilostazol group judged their outcome to be successful compared with 39% in the pentoxifylline group (P=.004) and 34% in the placebo group (P [is less than] .001).

RECOMMENDATIONS FOR CLINICAL PRACTICE

For patients with moderate to severe intermittent claudication, cilostazol results in longer walking distances than pentoxifylline. Future studies will need to address the symptomatic improvement gained over longer durations of therapy with cilostazol and in combination with a directed exercise program.

David Weismantel, MD Michigan State University East Lansing E-mail: david.weismantel@ht.msu.edu

COPYRIGHT 2001 Appleton & Lange
COPYRIGHT 2001 Gale Group

Return to Cilostazol
Home Contact Resources Exchange Links ebay